JPRN-UMIN000038553
Recruiting
未知
Special Drug Use Surveillance in Tamiflu-Resistant Influenza Viruses - Special Drug Use Surveillance in Tamiflu-Resistant Influenza Viruses
ConditionsInfluenza type A or B virus infection
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Influenza type A or B virus infection
- Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •No criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Post-marketing Surveillance Protocol Number; CDRB436I1401BRAF V600E mutation-positive unresectable advanced or recurrent solid tumorJPRN-jRCT2031230623sato masayuki90
Recruiting
Not Applicable
Protocol Number; CINC280AJP01MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancerJPRN-jRCT2031200409Sugimoto Toshiya100
Active, not recruiting
Not Applicable
Protocol Number; CLCZ696B1401JPRN-jRCT2031200432Sugimoto Toshiya660
Unknown
Not Applicable
EGEND study (Lansoprazole effectiveness on GERD patients with dyspepsia symptoms)Gastroesophageal reflux disease with dyspepsia symptomsJPRN-jRCT1080222261TAKEDA PHARMACEUTICAL COMPANY LTD.15,000
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100